Actos (pioglitazone) is a pharmaceutical drug prescribed to Type II diabetics which has been found to increase a patient's risk of developing bladder cancer. Two different FDA Actos bladder cancer warnings have been issued, stating that taking the drug for one year increases the risk of bladder cancer. The drug has been recalled in other countries, but is still being prescribed to patients in the United States.
Early clinical testing revealed that Actos posed a heightened risk for blader cancer, yet the drug company did not add a warning concerning Actos bladder cancer. As one of the most prescribed diabetes drugs ever, Actos brought Takeda Pharmaceuticals millions in profits. Unaware of the risk, countless Americans developed bladder cancer while taking Actos.
In October of 2015, Takeda Pharmaceuticals offered a settlement of $2.4 billion to settle more than 9,000 pending Actos bladder cancer lawsuits. Persons who have been diagnosed with bladder cancer and have a history of taking Actos, and family members who have lost a loved one to Actos bladder cancer, are among the plaintiffs. These attorneys are still accepting new claims from persons and family members affected by bladder cancer from Actos. Filing an Actos bladder cancer lawsuit is your means to exercise your legal rights and recover damages for losses and harm resulting from the disease.
This site features general information about Actos bladder cancer lawsuits. To speak with an attorney handling national* Actos lawsuits for bladder cancer, complete the contact form for a free, no-obligation Actos cancer lawsuit case review.
Actos bladder cancer is a risk for anyone who has used the diabetes drug Actos, especially patients who took this drug for more than a year. Takeda Pharmaceuticals has knowingly exposed consumers to an increased risk of developing deadly bladder cancer, continuing to market the drug even after the FDA released a safety warning on Actos bladder cancer and following an Actos recall in France.
The FDA issued two warnings on the risk of bladder cancer from taking Actos, in 2010 and 2011. Federal regulators required that Takeda Pharmaceuticals add a bladder cancer warning label to the drug in 2011. Read detailed information about FDA bladder cancer warnings here.
Persons and the family members of persons who have suffered from bladder cancer after being exposed to pioglitazone, the active ingredient in Actos, may still qualify to file an Actos bladder cancer lawsuit. Contact these attorneys to learn about contingency representation â€“ you'll never pay a legal fee unless they win on your behalf.
This page contains answers to questions commonly asked regarding an Actos bladder cancer lawsuit, such as, Who can file an Actos bladder cancer lawsuit? and What how much does it cost to file an Actos cancer lawsuit?
Our attorneys specialize in holding large corporations accountable when they've placed profits ahead of safety. Through settlements and winning verdicts, our attorneys have obtained millions for our clients. Let us help you today. Read more about Actos Bladder Cancer Attorneys.
A leader in cancer research at Harvard University asserts that perhaps 10,000 cases of ovarian cancer can be blamed each year on perineal talc use in the US. Despite the existence of evidence that talc-based products are dangerous and can cause cancer, talc is not regulated in the US. The American Cancer Society estimates that in 2013, about 22,240 new cases of ovarian cancer will be diagnosed, while 14,030 women will die as a result of ovarian cancer in the US.
Roundup weed killer, manufactured by Monsanto, uses a chemical called glyphosate, which the World Health Organization labeled as a probable carcinogen in 2015. Roundup is the most popular of all glyphosate-based herbicides. As little as 8 hours of Roundup exposure has been linked to an increased risk of non-Hodgkin lymphoma, multiple myeloma, and leukemia. Millions of gardeners, landscapers, farmers and others have been exposed to Roundup cancer risks.
Physiomesh is a form of surgical mesh that has been used in hernia repair surgeries. Ethicon Physiomesh was used in ventral hernia repair and has been pulled from the market due to a high failure rate. Persons with Ethicon Physiomesh have experienced an array of complications that include pain, infection, hernia recurrence, adhesion or scar-tissue buildup, intestinal blockage, bleeding, perforation, organ damage, and the need for revision surgery.